Cystic Fibrosis Flashcards

1
Q

Cystic Fibrosis

A
  • Progressive, life-limiting, genetic disorder
  • Autosomal recessive
  • More than half of CF population >= 18 y.o.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pathophysiology

A
  • Mutation of CFTR gene causing CFTR protein to dysfunction
  • Regulates chloride transport across cell membrane
  • Without cholride, mucus becomes thick and sticky
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

CF Mutations

A
  • Different mutations result in different levels of CFTR function
  • > 2000 mutations
  • F508del - most common mutation
  • Protein misfolded and doesn’t reach cell surface
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

CF Diagnosis

A
  • Newborn screening: measures immunoreactive trypsinogen, chemical made by pancreas
  • Gold standard: sweat test, sample of sweat collected from skin (Positive >=60 mmol/L of chloride)
  • Chromosomal analysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

CF Involved Organ Systems

A
  • GI
  • Hepatic
  • Pulmonary
  • Reproductive
  • Bone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Signs/Symptoms

A
  • Poor growth/weight gain
  • Meconium ileus
  • Frequent greasy, bulky stools OR difficulty in bowel
  • Frequent lung infections
  • Wheezing/SoB
  • Persistent coughing, occasional sputum
  • Chronic sinusitis
  • Very salty skin
  • Male infertility
  • Nasal polyps
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

GI Goals

A
  • Control pancreatic insufficiency by providing adequate enzyme supplementation
  • Optimize growth and nutritional status
  • Promote healthy bowel habits
  • Maintain normal vitamin levels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

GI Tract Manifestations

A
  • Insufficient secretion of pancreatic enzymes
  • Fat-soluble vitamin malabsorption
  • Insulin deficiency
  • Intestinal obstruction: meconium ileus, DIOS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Pancreatic Insufficiency

A
  • Maldigestion of nutrients
  • Symptoms: steatorrhea, frequent loose stools, flatulence, cramping, bloating, poor weight gain constipation
  • Below age-related norms of weight AND height
  • Result of pancreatic enzyme deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

PERT

A
  • Pancreatic Enzyme Replacement Therapy
  • Creon, Zenpep, Pancreaze, Ultresa, etc
  • Contain lipase, protease, amylase
  • Enzyme brands aren’t interchangeable
  • DR capsules with enteric-coated microspheres or minitablets
  • Porcine derived
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

PERT Dosing

A
  • Based on TBW or fat ingested
  • Dosed on lipase units
  • Taken with every meal and snack

Dosing Options

  • 500-2500 units/kg/meal
  • 10,000 units/kg/day
  • 4,000 units/g of dietary fat/day
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PERT Capsules

A
  • Do not crush or chew contents of DR capsules
  • Can open capsule and add to room temperature, acidic foods (applesauce)
  • Must eat immediately and follow with water, juice, formula, breast milk
  • Regular release tablets are swallowed whole with sufficient liquid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

PERT AE

A
  • Mucosal irritations
  • Fibrosing colonopathy and colonic strictures (high doses > 6000 lipase units/kg/meal): diarrhea, constipation, abdominal pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

PERT Monitoring

A
  • Stool fat content
  • Abdominal symptoms
  • Nutritional intake
  • Growth
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Fat Soluble Vitamins

A
  • Replace A, D, E, and K

- Doses higher compared to those without CF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Nutritional Intake

A
  • Energy intakes can be greater than standard for general population
  • BMI >50-85% for age
  • May require nutritional supplementations like EN
  • Promotes healthy pulmonary function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Insulin Deficiency

A
  • CF related diabetes
  • Prevalence increases with age
  • Associated with worse lung fxn, poorer nutritional status, increased pulm. infections
  • Shares features of DM I and II
  • Treat with insulin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

DIOS

A
  • Distal intestinal obstruction syndrome
  • Symptoms: cramping abdominal pain, poor appetite, abdominal distension
  • Therapy: electrolytes lavage solutions: passage of stool being symptom resolution
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Hepatic System + CF

A
  • Bile duct obstruction can lead to cirrhosis, portal hypertension
  • Ursodiol: controversial
  • Dosing: 15-20 mg/kg/day; divided BID
20
Q

Pulmonary Systems

A
  • Manifestations result from impaired mucociliary clearance resulting in accumulation of viscous mucus in airways
  • Consequences: obstruction, inflammation, infection
  • Chronic rhinitis, sinusitis, nasal polyps
21
Q

Pulmonary System Goals

A
  • Decrease long-term rate of lung fxn decline
  • Airway clearance techniques (ACT)
  • Anti-inflammatory agents
  • Mucus alteration
  • Restore airway surface liquid
  • Bronchodilators
  • Chronic antibiotics
22
Q

ACT

A
  • Improve ventilation, reduce accumulation of secretions
  • Done at least BID
  • Include chest/back percussions, exercise, percussion vest
  • Bronchodilator pre-treatment
23
Q

Ibuprofen Use

A
  • Anti-inflammatory Treatment
  • Decreased rate of decline of FEV1
  • Given to 6-17 y.o. with mild lung disease (FEV >= 60%)
  • [Peak plasma] = 50-100 mg/L
  • 20-30 mg/kg/dose given BID
24
Q

Azithromycin Use

A
  • Anti-inflammatory treatment
  • Unclear if anti-inflammatory effects are due to antimicrobial and/or immunomodulatory mechanisms
  • Slow decline in FEV1 in CF patients with Pseudomonas
  • Decreased pulmonary exacerbation
  • Dosing: 3x/week
25
Mucus Alteration Options
- Pulmozyme - Nebulized hypertonic saline - Mannitol inhalation powder
26
Pulmozyme
- Aerosolized recombinant dornase alfa (DNase) - Decreases viscosity of sputum - Clinical trial show modest improvements in DEV and pulmonary exacerbation - Dose: 2.5 mg nebulized once daily or BID - AE: hoarseness, voice alteration, and pharyngitis - Use selected nebulizer, compressor - Don't mix with other medications in nebulizer
27
Nebulized Hypertonic Saline
- Draws water into airways, improve mucus clearance - 3-7% nebulized daily to BID - Improve lung fxn, decrease exacerbations requiring antibiotics - May cause bronchospasm, pre-treat with bronchodilator - Hyper-Sal, PulmoSal, Nebusal (PulmoSal buffered with Na-bicarb)
28
Mannitol Inhalation Powder
- Bronchitol - Osmotic agent, draws water into the airways, thins mucus - 18 years of age and older - Dry powder inhaler - Bronchitol tolerance test - Albuterol prior to use - Inhale contents of 10 capsules twice daily - AE= bronchospasm, hemoptysis
29
Pulmonary Chronic Therapy
- Inhaled corticosteroids: if patient also has asthma, not used routinely - Inhaled SABAs: pre-treat for irritating inhaled therapies
30
Pulmonary Infection Pathogens
- S. aureus: major pathogen first year of life - H. influenzae: major pathogen by 3 y.o. - P. aeruginosa: Major pathogen by age 5, colonized - Burkholderia, Stenotrophomonas, Aspergillus, MRSA
31
Chronic Antibiotic Therapy
- Intention is to prolong time between acute exacerbations | - Usually inhaled: TOBI/Tobi podhaler, Cayston
32
TOBI
- Tobi Podhaler - Nebulized and dry powder inhaler formulations of tobramycin - P. aeruginosa colonization - Given BID: 28 days on treatment, 28 days off
33
Tobi Podhaler Administration
- 4 capsules inhaled BID - Inhale 2 times from each capsule - Take doses 12 hours apart - Store capsules in blister card until ready to use - Do not swallow capsules
34
Cayston
- Nebulized aztreonam - P. aeruginosa colonization - Give TID; 28 days on treatment, 28 days off - Altera nebulizer system
35
Sequence of Inhaled Medications
1. Bronchodilator 2. Hypertonic Saline 3. Pulmozyme 4. Airway clearance techniques 5. Aerosolized antibiotics
36
CF + Additional Systems
- Reproductive system: majority of males have congenital bilateral absence of the vas deferens - Bone disease: low bone density, secondary to vitamin D deficiency, systemic inflammation, corticosteroid use
37
Kalydeco
- Ivacaftor, CFTR modulator - Targets the defective CFTR protein, >= 4 month - Patient with specific mutations, not homozygous F508del - Improves: lung function, weight gain, QoL - Expensive
38
Kalydeco Dosing
- Reduce dose: moderate-severe hepatic impairment - CYP3A inhibitors: ketoconazole, fluconazole, adjust dose - Avoid: the strong inducers (CBZ, phenobarbital, phenytoin) - Avoid grapefruit - Give with fat containing food - Mix granules in 5 mL of soft food or liquid at or below room temperature (stable for 1 hour)
39
CFTR Modulator Warnings
- May increase hepatic transaminases: monitor liver fxn, baseline every 3 mo during 1st year of therapy and yearly after - Cataracts - CNS effects: dizziness, may impair abilities
40
Orkambi
-CFTR modulator -Lumacaftor + ivacaftor -2 copies of F508del, >= 2 years Drug Interactions -Lumacaftor: strong inducer CYP3A, avoid benzos and immunosuppressants -Hormonal contraceptives have decreased effectiveness -Respiratory AEs during initiation: chest discomfort, dyspnea
41
Symdeko
- CFTR modulator - Tezacaftor (100mg) + ivacaftor (150 mg) tablet and ivacaftor (150 mg) tablet - Co-packaged: take combo tablet in morning and monotherapy in evening - >= 6 y.o. with 2 copies of F508del or at least one mutation that is responsive
42
Trifakta
- CFTR modulator - Elexacaftor + tezacaftor + ivacaftor - >= 12 y.o. with at least one copy of F508del - Supplied as 2 separate products packaged together: Combination and ivacaftor
43
Acute Pulmonary Exacerbation
- New/increased cough, sputum production, dyspnea with exertion - Increased nasal congestion or drainage - Change in sputum appearance - Decreased exercise tolerance, energy, pulm fxn tests, appetite, weight - +/- Fever - Chest x-ray not routinely done, may not shown changes over baseline
44
Acute Pulmonary Exacerbation
- Diagnosis: changes from patient's baseline | - Goals: decrease pulmonary signs/symptoms, eradication of P. aeruginosa is unlikely
45
Acute Pulmonary Exacerbation Treatment
- Antibiotics oral or IV - Choice depends on cultures/sensitivity reports, dose at upper end (approach normal pop parameters with age) - P. aeruginosa generally uses aminoglycosides in combo with antipseudomonal penicillin - Increased nutrition - Increased ACT
46
Investigational Therapies
- New CFTR modulators - Antibiotics: inhaled levofloxacin - Non-porcine derived enzymes